News | January 23, 2026
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
This marks the second indication for which gumokimab has gained NDA review acceptance
This marks the second indication for which gumokimab has gained NDA review acceptance
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Over 8.8?million Indians aged 60 and above currently live with dementia,
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Subscribe To Our Newsletter & Stay Updated
